$10.79−0.50 (−4.43%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD
4D Molecular Therapeutics (FDMT) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
Business engineGrowing fast: revenue compounds ~47.4%/yr (FY21→FY25), net margin −164.4%. Worth your attention in FY25: Share count (+108.9%) and Returns vs FCF (n/m). Both visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)—
85.2
FY21→FY25CAGR +47.4%/yr
Net income ($M)▲12.9%
−140.1
FY21→FY25CAGR —
Free cash flow ($M)▲20.8%
−109.6
FY21→FY25CAGR —
Diluted EPS▲18.8%
−2.42
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+108.9%
27.7mn → 57.9mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.
Capex
$536.0K
−85.8% YoY in FY25 · 0.6% of revenue.
Returns vs FCF
n/m
$0.0M returned vs $−109.6M of FCF in FY25. Free cash flow was negative, so returns were funded from the balance sheet rather than from cash generation.
What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)
-164¢ of every revenue dollar becomes profit.
Margin trend · direction beats level Gross Operating Net
Over this window: gross 100.0% → 100.0%. Net margin -164.4% is below the sector median.
The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | 96,077.0 | 85,209.0 | 0.0 | 20,723.0 | 3,129.0 | 18,038.0 | — | +47.4% |
Cost of revenue | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — |
Gross profit | 96,077.0 | 85,209.0 | 0.0 | 20,723.0 | 3,129.0 | 18,038.0 | — | +47.4% |
Research & development | 260,646.0 | 195,696.0 | 141,299.0 | 97,096.0 | 80,253.0 | 61,360.0 | ▲38.5% | +33.6% |
Selling, general & admin | 52,565.0 | 49,060.0 | 46,579.0 | 36,494.0 | 32,908.0 | 28,011.0 | ▲5.3% | +15.0% |
Total operating expenses | 313,211.0 | 244,756.0 | 187,878.0 | 133,590.0 | 113,161.0 | 89,371.0 | ▲30.3% | +28.6% |
Operating incomefeeds ROC rank | −217,148.0 | −159,547.0 | −187,841.0 | −112,867.0 | −110,032.0 | −71,333.0 | ▲15.1% | — |
Other income, net | 16,793.0 | 19,438.0 | 26,973.0 | 12,030.0 | 2,538.0 | 16.0 | — | — |
Pretax income | −200,355.0 | −140,109.0 | −160,868.0 | −100,837.0 | −107,494.0 | −71,317.0 | ▲12.9% | — |
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings | −200,355.0 | −140,109.0 | −160,868.0 | −100,837.0 | −107,494.0 | −71,317.0 | ▲12.9% | — |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | −2.70 | −2.42 | −2.98 | −2.58 | −3.32 | −2.57 | ▲18.8% | — |
Diluted shares (mn) | 72.25 | 57.93 | 53.94 | 39.13 | 32.35 | 27.73 | ▲7.4% | +20.2% |
| Margins | ||||||||
Gross margin81st pct in Healthcare | 100.0% | 100.0% | — | 100.0% | 100.0% | 100.0% | — | — |
Operating margin | −226.0% | −187.2% | — | −544.6% | −3516.5% | −395.5% | — | — |
Net margin19th pct in Healthcare | −208.5% | −164.4% | — | −486.6% | −3435.4% | −395.4% | — | — |
† TTM = trailing four quarters through 2026-09-30.
2 more years of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-03-18 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was 4D Molecular Therapeutics' net income?
4D Molecular Therapeutics reported net income of −$140.1M in fiscal 2025, a net margin of −164.4%.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

